

BASIC AND CLINICAL ENDOCRINOLOGY/3

CYTOCHEMICAL BIOASSAYS

TECHNIQUES AND CLINICAL APPLICATIONS

edited by
J. Chayen
and
Lucille Bitensky

CYTOCHEMICAL BIOASSAYS

Techniques and Clinical Applications

Edited by

J. CHAYEN

LUCILLE BITENSKY

Division of Cellular Biology
Kennedy Institute of Rheumatology
London, England

MARCEL DEKKER, INC. New York and Basel
BUTTERWORTHS London

Library of Congress Cataloging in Publication Data

Main entry under title:

Cytochemical bioassays.

(Basic and clinical endocrinology ; 3)

Includes bibliographical references and indexes.

1. Hormones--Analysis--Addresses, essays, lectures.
 2. Cytochemical bioassays--Addresses, essays, lectures.
- I. Chayen, J. (Joseph), [date]. II. Bitensky, L. (Lucille), [date]. III. Series. [DNLN: 1. Biological assay--Methods. 2. Cytological techniques. 3. Cyto-diagnosis--Methods. 4. Hormones--Analysis. W1 BA813T v.3 / QY 330 C997].
- RB48.5.C95 1983 616.07'56 83-17661
- ISBN 0-8247-7001-3

COPYRIGHT ©1983 by MARCEL DEKKER, INC. ALL RIGHTS RESERVED

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system without permission in writing from the publisher.

MARCEL DEKKER, INC.

270 Madison Avenue, New York, New York 10016

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

Preface

In recent years there has been a resurgence of interest in bioassays. Two factors have contributed to this interest. The first is the fact that, in a proportion of cases, immunoassay has yielded results that are at obvious variance with the clinical and physiological status of the patient. The second is the development of sensitive in vitro bioassays that are at least as sensitive as the equivalent radio-immunoassays, so permitting comparison between immunoactivity and bioactivity. The most sensitive of these in vitro bioassays are the cytochemical bioassays that are at least one thousand times as sensitive as the equivalent radio-immunoassays. They have the further advantage that the same apparatus, and the same expertise, can be used for the bioassay of any polypeptide hormone. The cytochemical bioassay system has also proved to be of special value in helping to elucidate the mode of action of hormones. This use of the system has disclosed the existence of immunoglobulins that can block the effect of hormones.

These bioassays, and the cytochemical bioassay system, are now being used widely both for clarifying clinical conditions, such as the role of blocking antibodies in thyroid pathology, and for more academic research. Consequently we agreed with the editors of this series that the time seemed ripe to review this rapidly expanding field. We therefore invited some of the leading investigators to describe the cytochemical bioassay relevant to their investigations and to discuss the clinical and research implications of their findings.

J. Chayen and Lucille Bitensky

Contributors

J. ALAGHBAND-ZADEH, Ph.D., F.R.C. Path., Department of Chemical Pathology, Charing Cross Hospital Medical School, London, England

DEREK R. BANGHAM, M.B.B.S., F.R.C.P., Head of Division of Hormones, National Institute for Biological Standards and Control, London, England

PETER H. BAYLIS, M.D., F.R.C.P., Consultant Physician and Senior Lecturer in Medicine, Department of Medicine, Royal Victoria Infirmary and University of Newcastle Upon Tyne, Newcastle Upon Tyne, England

G. M. BESSER, M.D., F.R.C. Path., F.R.C.P., Department of Endocrinology, St. Bartholomew's Hospital, London, England

LUCILLE BITENSKY, D.Sc., M.R.C.P., Head of Laboratory Medical Histochemistry, and Deputy Head of Division of Cellular Biology, Division of Cellular Biology, Kennedy Institute of Rheumatology, London, England

GIAN FRANCO BOTTAZZO, M.D., M.R.C. Path., Senior Lecturer in Clinical Immunology, Department of Immunology, Middlesex Hospital Medical School, London, England

J. CHAYEN, D.Sc., Head of Division of Cellular Biology, Division of Cellular Biology, Kennedy Institute of Rheumatology, London, England

KLAUS-DIETER DÖHLER, Ph.D., Professor of Experimental Endocrinology, Department of Clinical Endocrinology, Medizinische Hochschule Hannover, Hannover, Federal Republic of Germany

DEBORAH DONIACH, M.D., F.R.C.P., Emeritus Professor Clinical Immunology, Department of Immunology, Middlesex Hospital Medical School, Arthur Stanley Institute, London, England

H. A. DREXHAGE, M.D.,* Senior Lecturer in Clinical Immunology, Department of Immunology, Arthur Stanley House, Middlesex Hospital Medical School, London, England

D. EMRICH, M.D., Professor of Medicine and Nuclear Medicine, Department of Nuclear Medicine, Universität Göttingen, Göttingen, Federal Republic of Germany

STEPHEN FENTON, B.Sc., Department of Medicine, Charing Cross Hospital Medical School, London, England

TAKUMA HASHIMOTO, M.D.,** Research Fellow of Alexander von Humboldt Stiftung, Department of Clinical Endocrinology, Medizinische Hochschule Hannover, Hannover, West Germany

RONALD W. HOILE, M.S., F.R.C.S., Lecturer in Surgery, Surgical Unit, St. Stephens Hospital, London, England

JULIA C. JONES, M.Sc., Department of Medicine, Charing Cross Hospital Medical School, London, England

G. NEIL KENT, B.Sc., Ph.D.,† Division of Inherited Metabolic Diseases, M.R.C. Clinical Research Centre, Harrow, Middlesex, England; Division of Cellular Biology, Kennedy Institute of Rheumatology, London, England; and Department of Endocrine Physiology and Pharmacology, National Institute for Medical Research, London, England

NIGEL LOVERIDGE, Ph.D., Deputy Head WHO Collaborating Centre for Cytochemical Bioassays, Division of Cellular Biology, Kennedy Institute of Rheumatology, London, England

CHRISTOPH LUCKE, M.D.,‡ Department of Clinical Endocrinology, Medizinische Hochschule Hannover, Hannover, Federal Republic of Germany

Present affiliations

*Department of Pathology, Free University Hospital, Amsterdam, The Netherlands

**Assistant Professor of Medicine, The Central Clinical Laboratory, Kanazawa University Hospital, Kanazawa, Japan

†Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre, Nedlands, Western Australia

‡Professor and Head Physician, Hagenhoff-Klinik, Langenhagen, Federal Republic of Germany

GRAHAM A. MacGREGOR, F.R.C.P., Senior Lecturer/Honorary Consultant Physician, Department of Medicine, Charing Cross Hospital Medical School, London, England

J. MAXWELL McKENZIE, M.D., Professor and Chairman, Department of Medicine, University of Miami School of Medicine, Miami, Florida

ALEXANDER von zur MÜHLEN, M.D., Professor of Internal Medicine, Chairman of the Department of Clinical Endocrinology, Medizinische Hochschule Hannover, Hannover, Federal Republic of Germany

THOMAS O. F. WAGNER, M.D., Department of Clinical Endocrinology, Center of Internal Medicine and Dermatology, Medizinische Hochschule Hannover, Hannover, Federal Republic of Germany

W. H. C. WALKER, F.R.C. Pathol., F.R.C.P.(C), Professor of Pathology, McMaster University Medical Centre, Hamilton, Ontario, Canada

H. E. de WARDENER, M.D., F.R.C.P., Emeritus Professor of Medicine, Research Laboratories, Charing Cross Hospital Medical School, London, England

J. A. H. WASS, M.D., M.R.C.P., Senior Lecturer and Honorary Consultant Physician, Department of Endocrinology, St. Bartholomew's Hospital, London, England

JUDITH WEISZ, M.B., B.Chir., Chief, Division of Reproductive Biology, Department of Obstetrics and Gynecology, The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania

HANS K. WEITZEL, M.D.,* Department of Clinical Endocrinology, Medizinische Hochschule Hannover, Hannover, Federal Republic of Germany

MARGITA ZAKARIJA, M.D., Professor of Medicine, Department of Medicine, University of Miami School of Medicine, Miami, Florida

JOAN M. ZANELLI, Ph.D., Senior Scientific Staff, Hormones Division, National Institute for Biological Standards and Control, London, England

Present affiliation

*Professor and Chairman, Department of Obstetrics and Gynecology, Steglitz Clinic, Free University of Berlin, Berlin, Federal Republic of Germany

CYTOCHEMICAL BIOASSAYS

about the book . . .

This authoritative volume provides comprehensive coverage of *Cytochemical Bioassays*—a powerful, in vitro technique one thousand times more sensitive than equivalent radio-immunoassays. With contributions by 29 leading international experts, this single-source reference provides the information required for thorough understanding and effective application of this advanced methodology.

For each hormone examined, *Cytochemical Bioassays* offers complete guidelines to the assay—from basic endocrinology to procedures and analyzing the results. Research and clinical endocrinologists, biochemists, clinical chemists, pathologists, molecular and cell biologists, and geneticists will welcome this important information as a vital aid to their work.

about the editors . . .

J. CHAYEN is Head of the Division of Cellular Biology at the Kennedy Institute of Rheumatology, London, England. In addition, he serves as Head of the designated laboratory for cytochemical bioassays and a member of the Expert Advisory Panel on Biological Standardization of the World Health Organization. Dr. Chayen received the Ph.D. degree from King's College, London and the D.Sc. degree from the University of London. He is a member of the Endocrine Society, Society for Endocrinology, Biochemical Society, Royal Society of Medicine, and Institute of Physics, and a Fellow of the Institute of Biology.

LUCILLE BITENSKY is Head of the Laboratory of Medical Histochemistry and Deputy Head of the Division of Cellular Biology, Kennedy Institute of Rheumatology, London, England. Dr. Bitensky has also served as a Visiting Professor at the Royal Free Hospital School of Medicine, University of London (1972-1981) and McGill University, Montreal, Canada (1978). She received the Ph.D. and D.Sc. degrees from the University of London and the M.B.B.Ch degree from University of Witwatersrand, South Africa. Dr. Bitensky is a Fellow of the Royal College of Pathologists and a member of the Royal College of Physicians of London, as well as the Endocrine Society, Society for Endocrinology, Biochemical Society, and Royal Society of Medicine.

Printed in the United States of America

ISBN: 0-8247-7001-3

Contents

Preface *iii*

Contributors *v*

1. General Introduction to Cytochemical Bioassays 1

J. Chayen and Lucille Bitensky

Origins 1

The Need for Sensitive Bioassays of Polypeptide Hormones 2

Functional Versus Analytical Assays 3

The Advantages of Cytochemical Bioassays 4

References 5

2. What's in a Bioassay? 7

Derek R. Bangham

General 7

Biometric Requirements and Considerations 10

Biological Assay Systems 16

Some Practical Points 22

Standards as Calibration Materials 25

Appendix A: Glossary 32

Appendix B: Table of Biological Standards and Reference Materials 35

References 40

3. The Techniques of Cytochemical Bioassays 45*Nigel Loveridge*

Introduction	45
Maintenance Culture	46
Chilling, Sectioning, and Reaction Methods	51
Section Assays	60
Measurement	63
Interpretation	69
Appendix: The Composition of Trowell's T8 Culture Medium	77
References	77

4. Adrenocorticotropic Hormone 83*W. H. C. Walker*

Adrenocorticotropin: Structure and Function	83
Assays Available for Adrenocorticotropin	87
The Cytochemical Bioassay	89
Validation of the Cytochemical Bioassay	92
Physiological Studies and Clinical Investigations	98
Future Clinical Applications	100
References	100

5. Thyroid-Stimulating Hormone 107*Klaus-Dieter Döhler, Alexander von zur Mühlen, Thomas O. F. Wagner, Christoph Lucke, Hans K. Weitzel, Takuma Hashimoto, and D. Emrich*

Nature of Thyroid-Stimulating Hormone, Its Origin, Release, and Biological Function	107
Development and Nature of Assay Systems for the Determination of TSH	108
Methodology of the Cytochemical Bioassay for TSH	109
Evaluation of the Cytochemical Bioassay for TSH	112
Clinical Applications of the CBA for TSH	116
Summary and Discussion	127
References	130

6. The Thyroid-Stimulating Antibody of Graves' Disease	135
Part I. General Concepts and Assay Materials	135
<i>J. Maxwell McKenzie and Margita Zakarija</i>	
Introduction	135
Current Assay Systems	138
Clinical Correlations of the Assay of TSAb by the cAMP Slice Assay	140
The Immunochemistry of TSAb: The Possibility of Developing an Immunoassay	142
Part II. The Cytochemical Bioassay	143
<i>Lucille Bitensky and J. Chayen</i>	
Procedure	143
Validation	144
Preparation of the Sample for Assay	144
Time Course of the Response	145
Discrimination Between TSH and TSAb	146
Comparison with Other Assays	147
Results with the Cytochemical Bioassay	147
TSAb Produced In Vitro	147
References to Part I	148
References to Part II	151
 7. Thyroid Growth Stimulating and Blocking Immunoglobulins	 153
<i>H. A. Drexhage, Gian Franco Bottazzo, and Deborah Doniach</i>	
Introduction	153
Two Quantitative Cytochemical Techniques for the Detection of TGI and TGI-B	155
Results with the Nucleic Acid Cytophotometry Assay System	161
Results with Cytochemical Measurements of Glucose-6-Phosphate Dehydrogenase Activity	165
Future Developments	169
References	171

8. Luteinizing Hormone: A New Generation of Bioassays 173*Judith Weisz*

Introduction	173
Structure of LH	175
Bioassays for LH and HCG: Old and New Generations	176
Applications for the New Generation of Bioassay	180
Projections for the Future	182
References	183

9. Technique and Clinical Relevance of a Cytochemical Bioassay for Gastrin-like Activity 189*Ronald W. Hoile*

Introduction	189
The Nature of Gastrin	189
Cytochemical Section Bioassay for Gastrin-like Activity	191
Validation of the Assay	196
Application of the Cytochemical Section Bioassay for Gastrin-like Activity	202
Clinical Relevance of Gastrin	205
The Need for a Cytochemical Bioassay of Gastrin-like Activity	213
Zollinger-Ellison Syndrome	214
Conclusions	218
References	221

10. Measurement of Antidiuretic Hormone 225*Peter H. Baylis*

Introduction	225
Physiology of Antidiuretic Hormone	226
Measurement	231
The Cytochemical Bioassay	237
Conclusions	248
References	249

11. Parathyroid Hormone 255*G. Neil Kent and Joan M. Zanelli*

Nature of the Hormone	255
Biological Activity	257
Metabolism of PTH	258
Physiological Role of PTH	258
Structure-Function Relationships	264
Why Measure Circulating Levels of PTH?	266
Assays of Circulating PTH: Techniques, Validation, Problems	266
Applications of the Cytochemical Bioassay of PTH	279
Structure-Function Relationships of PTH and Future Developments of the Cytochemical Bioassay	292
References	295

12. A Cytochemical Bioassay for Angiotensin II 309*Julia C. Jones, J. Alaghband-Zadeh, and Graham A. MacGregor*

Introduction	309
Bioassay of Angiotensin II	314
Radioimmunoassay	318
Cytochemical Bioassay of Angiotensin II	321
References	326

13. Hypothalamic Regulating Hormones 333*J. A. H. Wass and G. M. Besser*

Introduction	333
Thyrotropin-Releasing Hormone: Isolation and Structure	334
Luteinizing Hormone Releasing Hormone: Gonadotropin-Releasing Hormone	337
Somatostatin	340
Corticotropin-Releasing Factor	342
Prolactin-Inhibiting Factor	343
Measurement of Hypothalamic Regulatory Hormones in Biological Systems	344
Editors' Note: Cytochemical Bioassays of Releasing Hormones	345
Note Added in Proof	346
References	347

14. Natriuretic Hormone 355

H. E. de Wardener, Stephen Fenton, and J. Alaghbnad-Zadeh

Mechanism of Action 356

Nature of the Circulating ($\text{Na}^+\text{-K}^+$)-ATPase Inhibitor 358

Site of Production 358

Clinical Relevance 359

Methods Used to Detect Natriuretic Hormone 363

Results Obtained Using Cytochemical Techniques for ($\text{Na}^+\text{-K}^+$)-ATPase
and G6PD Activity to Measure the Relative Concentration of
Natriuretic Hormone in Plasma and Hypothalamus 371

Conclusion 377

References 377

Author Index 381

Subject Index 405

1

General Introduction to Cytochemical Bioassays

J. Chayen and Lucille Bitensky / Kennedy Institute of Rheumatology,
London, England

ORIGINS

Quantitative cytochemistry, as it is used in the cytochemical bioassays, was developed over many years as a form of truly cellular biochemistry, that is, the measurement of metabolic activity or of active moieties in individual cells within a histologically complex tissue. These developments have been discussed elsewhere (Chayen and Bitensky, 1968; Chayen, 1978a; 1980). To achieve this histological specificity, the sensitivity of measurement had to be increased so that the activity of one cell could be measured, as contrasted with the mean activity of one million cells that is used in conventional biochemistry. This was done by the use of scanning and integrating microdensitometry, which had been developed earlier (Deeley, 1955) for measuring the amount of Feulgen stain (for DNA) in individual nuclei. It is now clear that microdensitometry of individual cells yields results that are quantitatively comparable to those obtained by more conventional procedures, done on aliquots of 10^6 cells (Chayen, 1978b; Olsen et al., 1981).

The methods of quantitative cytochemistry depend on chilling the tissue, and sectioning it at low temperature, without producing any observable ice artifact. Perhaps the best validation of these techniques (Chayen and Bitensky, 1968; Chayen, 1978a) is the fact that sections, prepared by the techniques described in Chapter 3, respond to the relevant polypeptide hormone with the same sensitivity as do the segments of the target organ. Methods were then devised for

retaining the integrity of the undenatured sections during the cytochemical reaction designed for disclosing the required enzymatic or other activity (as discussed in Chapter 3). The aim of quantitative cytochemistry is to precipitate the colored reaction product in the cell in which the chemical activity resides. The section is then inspected in the microdensitometer to determine the histology and to identify the target cells; the instrument can then measure the amount of reaction product specifically in these cells.

At the same time as the methods of quantitative cytochemistry were being developed, recourse was being made to the system of nonproliferative organ maintenance culture that had been developed by Trowell (1959). Thus, for example, samples of human synovial tissue were maintained *in vitro*, with no apparent change either in histology or in biochemical activity (Chayen and Bitensky, 1982), in order to test the effect of anti-inflammatory agents.

These methods, both of maintenance culture and of quantitative cytochemistry, found use in many diverse applications (Pattison et al., 1979). About 1970, the late Professor John Daly suggested that, because of their sensitivity and because they could measure changes solely in the target cells, they ought to be applicable to the development of very sensitive bioassays of polypeptide hormones. At that time, his interest in adrenocorticotrophic hormone (ACTH) coincided with our rheumatological interest in this hormone. The first demonstration of the feasibility of this project was given in 1971 (Chayen et al., 1971). The first cytochemical bioassay, which was for ACTH, followed shortly (Chayen et al., 1972).

THE NEED FOR SENSITIVE BIOASSAYS OF POLYPEPTIDE HORMONES

For polypeptide hormones at least, there can be no doubt that "the hormone" is a biological concept and must be measured by the biological activity which it evinces. Consequently, for many years, such hormones were detected, defined, and measured by *in vivo* bioassay. However, these generally proved to be too insensitive for measuring normal circulating levels in humans or in animals; the best that they could achieve was to demonstrate excessively high circulating levels. [It may be remarked that, according to some authorities, such as Orth (1977), this is the most clinically useful purpose of assays.]

The advent of radioimmunoassay, and now of the other types of immunological assay, produced profound changes in the assaying of polypeptide (and other) hormones. The much improved sensitivity over the older *in vivo* bioassays, made it possible, in most cases, to measure the normal circulating levels of these hormones and to define conditions in which there was excessive, or too little, secretion of the hormone. The fact that these immunoassays could be automated gained them ready acceptance in routine clinical chemistry.